{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","groupDescription":"\\<1% PD-L1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A vs Treatment B","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.92"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","groupDescription":"≥1% PD-L1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A vs Treatment B","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.72"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"23.9","value":"17.3"},{"groupId":"OG001","lowerLimit":"13.4","upperLimit":"20.8","value":"16.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"<1% PD-L1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.8","upperLimit":"21.5","value":"18.0"},{"groupId":"OG001","lowerLimit":"11.6","upperLimit":"15.4","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"title":"≥1% PD-L1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by overall survival (OS) analysis. OS was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W","id":"OG000","title":"Treatment A"},{"description":"Pemetrexed 500 mg/m\\^2 + Cisplatin 75 mg/m\\^2 or Carboplatin 5 AUC up to 6 cycles","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All PD-L1 evaluable participants with baseline expression \\<1% or ≥1%","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of death (Up to 76 Months)","title":"Overall Survival (OS) According to PD-L1 Expression Level","type":"SECONDARY","unitOfMeasure":"Months"}